Intravenous Magnesium and Hospital Outcomes in Children Hospitalized With Asthma.
Journal
Hospital pediatrics
ISSN: 2154-1671
Titre abrégé: Hosp Pediatr
Pays: United States
ID NLM: 101585349
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
pubmed:
3
7
2021
medline:
30
10
2021
entrez:
2
7
2021
Statut:
ppublish
Résumé
Use of intravenous magnesium (IVMg) for childhood asthma exacerbations has increased significantly in the last decade. Emergency department administration of IVMg has been shown to reduce asthma hospitalization, yet most children receiving IVMg in the emergency department are subsequently hospitalized. Our objective with the study was to examine hospital outcomes of children given IVMg for asthma exacerbations. We conducted a retrospective cohort study using data from the Pediatric Health Information System. We used propensity score matching to compare children who received IVMg on the first day of hospitalization with those who did not. Primary outcomes were initiation and duration of noninvasive positive pressure ventilation. Secondary outcomes included mechanical ventilation (MV) initiation, duration of MV, length of stay, and subsequent tertiary medication use. Primary analysis was restricted to children admitted to nonintensive care inpatient units. Overall, 91 309 hospitalizations met inclusion criteria. IVMg was administered in 25 882 (28.4%) children. After propensity score matching, IVMg was not significantly associated with lower initiation (adjusted odds ratio 0.88; 95% confidence interval [CI] 0.74-1.05) or shorter duration of noninvasive positive pressure ventilation (rate ratio 0.94; 95% CI 0.87-1.02). Similarly, no significant associations were seen for MV initiation, MV duration, or length of stay. IVMg was associated with lower subsequent tertiary medication use (adjusted odds ratio 0.66; 95% CI 0.60-0.72). However, the association was lost when ipratropium was removed from the tertiary medication definition. IVMg administration was not significantly associated with improved hospital outcomes. Further study is needed to inform the optimal indications and timing of magnesium use during hospitalization.
Sections du résumé
BACKGROUND
Use of intravenous magnesium (IVMg) for childhood asthma exacerbations has increased significantly in the last decade. Emergency department administration of IVMg has been shown to reduce asthma hospitalization, yet most children receiving IVMg in the emergency department are subsequently hospitalized. Our objective with the study was to examine hospital outcomes of children given IVMg for asthma exacerbations.
METHODS
We conducted a retrospective cohort study using data from the Pediatric Health Information System. We used propensity score matching to compare children who received IVMg on the first day of hospitalization with those who did not. Primary outcomes were initiation and duration of noninvasive positive pressure ventilation. Secondary outcomes included mechanical ventilation (MV) initiation, duration of MV, length of stay, and subsequent tertiary medication use. Primary analysis was restricted to children admitted to nonintensive care inpatient units.
RESULTS
Overall, 91 309 hospitalizations met inclusion criteria. IVMg was administered in 25 882 (28.4%) children. After propensity score matching, IVMg was not significantly associated with lower initiation (adjusted odds ratio 0.88; 95% confidence interval [CI] 0.74-1.05) or shorter duration of noninvasive positive pressure ventilation (rate ratio 0.94; 95% CI 0.87-1.02). Similarly, no significant associations were seen for MV initiation, MV duration, or length of stay. IVMg was associated with lower subsequent tertiary medication use (adjusted odds ratio 0.66; 95% CI 0.60-0.72). However, the association was lost when ipratropium was removed from the tertiary medication definition.
CONCLUSIONS
IVMg administration was not significantly associated with improved hospital outcomes. Further study is needed to inform the optimal indications and timing of magnesium use during hospitalization.
Identifiants
pubmed: 34210764
pii: hpeds.2020-004770
doi: 10.1542/hpeds.2020-004770
pmc: PMC8591772
mid: NIHMS1749893
doi:
Substances chimiques
Ipratropium
GR88G0I6UL
Magnesium
I38ZP9992A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
785-793Subventions
Organisme : NHLBI NIH HHS
ID : K12 HL137943
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL136842
Pays : United States
Informations de copyright
Copyright © 2021 by the American Academy of Pediatrics.
Déclaration de conflit d'intérêts
POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Références
Pediatr Pulmonol. 2018 Jul;53(7):866-871
pubmed: 29660840
Pediatr Pulmonol. 2016 Dec;51(12):1414-1421
pubmed: 27218606
J Pediatr. 2020 May;220:165-174.e2
pubmed: 32147221
Acad Emerg Med. 2010 Nov;17(11):1189-96
pubmed: 21175517
JAMA Pediatr. 2016 Sep 1;170(9):878-86
pubmed: 27398908
Pediatr Crit Care Med. 2016 Feb;17(2):e29-33
pubmed: 26649938
Am J Emerg Med. 2007 Jan;25(1):6-9
pubmed: 17157675
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Am J Clin Nutr. 2016 Aug;104(2):247-58
pubmed: 27413128
Lancet Respir Med. 2013 Jun;1(4):301-8
pubmed: 24429155
Cochrane Database Syst Rev. 2016 Apr 29;4:CD011050
pubmed: 27126744
J Hosp Med. 2020 Jun 17;15(7):403-406
pubmed: 32584247
J Pediatr. 1996 Dec;129(6):809-14
pubmed: 8969721